The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Key takeaways
- Gilead Sciences is a drug manufacturing business with stocks listed on the NASDAQ.
- To buy shares in Gilead Sciences you'll need a platform that offers access to US markets.
- Use the GILD ticker symbol to find Gilead Sciences on your chosen trading platform and consider fractional shares if you want to start small.
Gilead Sciences Inc (GILD) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$N/A. During the previous open market day, the price has varied from a low of USDN/A to a high of USDN/A. Gilead Sciences is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Gilead Sciences
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Gilead Sciences. Find the share by name or ticker symbol: GILD. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy Gilead Sciences shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
Have Gilead Sciences's shares ever split?
Gilead Sciences's shares were split on a 2:1 basis on 27 January 2013. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.
Gilead Sciences shares at a glance
Information last updated 2025-12-01.
| 52-week range | US$86.7303 - US$128.7 |
|---|---|
| 50-day moving average | US$119.6052 |
| 200-day moving average | US$112.5295 |
| Target price | US$130.6336 |
| PE ratio | 19.4799 |
| Dividend yield | US$3.14 (2.46%) |
| Earnings per share (TTM) | US$6.46 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Is it a good time to buy Gilead Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying Gilead Sciences stock?
Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gilead Sciences's P/E ratio
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Gilead Sciences shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gilead Sciences's PEG ratio
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2292. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gilead Sciences's EBITDA
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$14.1 billion (£10.6 billion).
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure stock profitability.
Gilead Sciences share price volatility
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as US$86.7303 up to US$128.7. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.334. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
Gilead Sciences financials
| Revenue TTM | US$29.1 billion |
|---|---|
| Operating margin TTM | 45.23% |
| Gross profit TTM | US$22.9 billion |
| Return on assets TTM | 12.57% |
| Return on equity TTM | 40.71% |
| Profit margin | 27.88% |
| Book value | 17.343 |
| Market capitalisation | US$156.1 billion |
| EBITDA | US$14.1 billion |
TTM: trailing 12 months
Gilead Sciences share dividends
Dividend payout ratio: 38.58% of net profits
Recently Gilead Sciences has paid out, on average, around 38.58% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.51% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 2.51% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $3.14 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that Gilead Sciences may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 29 December 2025. The latest dividend was paid out to all shareholders who bought their shares by 14 December 2025 (the "ex-dividend date").
Gilead Sciences's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Gilead Sciences's total ESG risk score
Total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Gilead Sciences's environmental score
Environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Gilead Sciences's social score
Social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Gilead Sciences's governance score
Governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Gilead Sciences's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Gilead Sciences Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.15 |
|---|---|
| Total ESG percentile | 30.98 |
| Environmental score | 0.53 |
| Environmental score percentile | 2 |
| Social score | 12.97 |
| Social score percentile | 2 |
| Governance score | 7.65 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Gilead Sciences overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Frequently asked questions
Sources
More resources on Finder
Ask a question
More guides on Finder
-
Best short term investments in Australia for 2025
If you have funds to invest for 2 or years or less, you can safely earn up to 5% p.a. through a high interest savings account, bonds or ETFs.
-
The best ASX penny stocks (updated weekly)
Best performers included European Metals Holdings, True North Copper and Cobre.
-
How to buy Washington H. Soul Pattinson and Company shares in Australia
Steps to owning and managing Washington H. Soul Pattinson and Company shares from in Australia.
-
How to invest in copper in Australia
Copper is an industrial metal with many applications. Here’s what you should consider before investing.
-
How to invest in financial stocks in Australia
Financial stocks drive the economy and affect many aspects of a consumer’s economic life.
-
How to invest in the S&P 500
Find out the different ways you can invest in the S&P 500 index from Australia.
-
How to buy Viva Energy shares in Australia
Steps to owning and managing Viva Energy shares from in Australia.
-
How to buy Wells Fargo shares in Australia
Steps to owning and managing Wells Fargo shares from in Australia.
-
How to buy Visa shares in Australia
Steps to owning and managing Visa shares from in Australia.
-
How to invest in cannabis stocks
Just 5 years ago, few investors took cannabis stocks seriously; today, as billions of dollars pour into the sector, few doubt that it will be one of the next big disruptors.